Clearmind Medicine (CMND) announced positive top-line results from the first cohort of its Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate for the treatment of Alcohol Use Disorder, AUD. The top-line data from the first cohort demonstrate a favorable safety profile, with no serious adverse events reported and the treatment generally well-tolerated across all participants. Additionally, the cohort showed strong treatment observance, with high adherence to the dosing regimen and protocol requirements, underscoring the feasibility and patient acceptability of CMND-100 in a clinical setting.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine files Israeli patent for depression treatment
- Psychedelic: Atai Beckley, Cybin report quarterly earnings
- Clearmind Medicine receives final approval to expand Phase 1/2a AUD trial
- Clearmind announces notice of publication of patent for MEAI in China
- Clearmind Medicine completes first cohort treatment in Phase I/IIa AUD trial